Chimeric Rotavirus Antigen Complex for Cross-Protective Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for rotavirus and hepatitis A are inadequate in providing cross-protection and are costly due to high rates of infection among children and increasing cases in developing and developed countries, necessitating the development of a more effective and cost-efficient vaccine solution.
Innovation Solution
A recombinant antigen complex is created using a baculovirus expression vector system that expresses both rotavirus and hepatitis A virus antigens, forming a virus-like particle to induce immunogenicity and provide cross-protection against both viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate vaccines for rotavirus and hepatitis A are administered, then protection against both viruses is achieved, but vaccination cost and complexity increase
Solution Approach 1:
The patent combines two separate vaccine antigens (rotavirus VP7 and hepatitis A virus D3) into a single chimeric antigen expression vector. This merging allows both vaccines to be produced together in the same insect cell system, reducing the number of separate vaccination administrations needed and simplifying the overall vaccination system while maintaining protection against both viruses
2Productivity
If high production capacity is achieved for vaccine antigens, then vaccine availability improves, but production cost may increase
Solution Approach 1:
The patent creates a universal baculovirus expression vector system that can simultaneously produce multiple vaccine antigens (rotavirus and hepatitis A virus antigens) using the same insect cell host. This multi-functional system allows high production capacity for both antigens while utilizing shared production infrastructure, thereby reducing overall manufacturing costs compared to producing each antigen separately
3Reliability
If cross-protection against multiple viruses is provided, then vaccine effectiveness improves, but antigen complexity increases
Solution Approach 1:
The patent creates a composite chimeric antigen by fusing the rotavirus VP7 antigen with the hepatitis A virus D3 antigen in a single polypeptide construct. This composite antigen structure enables cross-protection against both viruses simultaneously while being expressed as a single unified protein molecule, reducing the complexity of multiple separate antigen administrations
Data Source
AI summary
Disclosed are a construct for expressing a rotavirus antigen complex loaded with a heterologous virus epitope, a vaccine composition containing the rotavirus antigen complex, a virus-like particle of rotavirus containing the rotavirus antigen complex, and a vaccine composition containing the virus-like particle of rotavirus. According to the present disclosure, an antigen complex containing a rotavirus antigen as well as a heterologous virus epitope and a virus-like particle of rotavirus containing the antigen complex can be produced in large scale at low cost. Thus, the present disclosure may be applied for research and development of novel complex vaccines for rotavirus and heterologous virus.